Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 14,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity Trial of IHV01

NCT02756208
View directory record Official record
Conditions
HIV Infection
Interventions
300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710
View directory record Official record
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Nov 13, 2026, 2:08 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 3 Interventional

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

NCT00308191
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate, Tiotropium Bromide
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT03259620
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006, CLS006 Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Hot Springs, Arkansas • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 4 Interventional

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

NCT00732524
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glipizide, Glipizide and Glargine
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Not applicable Interventional

Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.

NCT07270380
View directory record Official record
Conditions
Osteomyelitis
Interventions
genex with gentamicin (genex G)
Device
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
San Diego, California • Indianapolis, Indiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT05559580
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Avenciguat (BI 685509), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Not applicable Interventional

Intensive Case Management Between VA and Community Care for Suicide Prevention

NCT07534358
View directory record Official record
Conditions
Suicidal Ideation, Mental Health Issue, Social Determinants of Health
Interventions
SUicidE PRevention intensive CasE management and coorDination in Community CarE (SUPERCEDE), Present centered therapy
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Not applicable Interventional Results available

Suicide Prevention Study of VA-BIC in the Veteran Population

NCT04446468
View directory record Official record
Conditions
Suicide Prevention
Interventions
PEACE, Standard Psychiatric Hospital Discharge Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Enrolling by invitation Not applicable Interventional

Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B

NCT06311591
View directory record Official record
Conditions
Suicidal Ideation, Suicide Attempt, Self Harm
Interventions
Jaspr App
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
27,908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Phase 2 Interventional

Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.

NCT04839497
View directory record Official record
Conditions
Amputation
Interventions
Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees
Combination Product
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 13, 2026, 2:08 AM EST
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

NCT06307626
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Recruiting Phase 2Phase 3 Interventional

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Oakland, California • Orange, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 3 Interventional Results available

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

NCT00347360
View directory record Official record
Conditions
Hypertension
Interventions
lisinopril, carvedilol controlled release formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
151
States / cities
Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Nov 13, 2026, 2:08 AM EST
Not yet recruiting Not applicable Interventional

Miniature In-line Respirator

NCT07768215
View directory record Official record
Conditions
Brain Death, Respiration, Artificial
Interventions
Hope inVent
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 13, 2026, 2:08 AM EST
Completed Phase 2 Interventional Results available

Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

NCT00869440
View directory record Official record
Conditions
Procedural Sedation, Endoscopy
Interventions
CNS 7056, Midazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Nov 13, 2026, 2:08 AM EST